. . . . . . . . . . . . . . . . . . "a(SCHEM:\"serum insulin\") -> kin(complex(NCM:\"p85/p110 PI3Kinase Complex\"))" . "p(MGI:Rbp4) -| (a(SCHEM:\"serum insulin\") -> kin(complex(NCM:\"p85/p110 PI3Kinase Complex\")))" . "Approximately 61,000 statements." . "Copyright (c) 2011-2012, Selventa. All rights reserved." . "BEL Framework Large Corpus Document" . . "1.4" . "Fenretinide treatment did not affect food intake, body weight or the development of obesity on the high-fat diet (not shown). Mice on a high-fat diet developed marked insulin resistance (Fig. 4d) and glucose intolerance (Fig. 4e). Fenretinide treatment improved insulin sensitivity (Fig. 4d) and normalized glucose tolerance (Fig. 4e). Similar results were obtained in ob/ob mice treated with fenretinide (not shown). Thus, both genetic and pharmacological interventions that decrease serum RBP4 levels improve insulin sensitivity. RBP4 impairs insulin signalling in muscle To understand how RBP4 alters insulin sensitivity, we studied insulin signalling in muscle and liver of Rbp4-/- mice and mice overexpressing human RBP4 (RBP4-Tg mice). Basal phosphoinositide 3-kinase (PI(3)K) activity was similar in all genotypes (Fig. 5a-d). Insulin resulted in a 26-fold increase in PI(3)K activity in muscle of control mice, but its effect was reduced by 30% in RBP4-Tg mice (Fig. 5a)." . . "Selventa" . . . . "2014-07-03T14:30:36.957+02:00"^^ . . .